Sulfadoxine- pyrimethamine+ amodiaquine dispersible

Access

-

Approved

Supyra®

S Kant

Paediatric formulation

Intermittent preventative treatment (TPP-1)

Therapeutic indication	Seasonal Malaria Chemoprevention (SMC) for children most at risk of severe malaria in areas with seasonal malaria transmission
Dosing	Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles during peak malaria transmission season
Efficacy	75% reduction in malaria episodes in pivotal trials
Key features	Recommended by WHO since 2012 for the prevention of malaria in children in areas of high seasonal malaria transmission 2-year shelf life
Challenges	Drug distribution via door-to-door campaigns
Status	WHO prequalification obtained in April 2021 2^nd taste-masked and dispersible SPAQ formulation prequalified by WHO Registered in 6 countries; ongoing in 5 other countries 45.4 million treatments delivered cumulatively since WHO PQ
Next milestone	Validation of dose and development of packaging or formulation for children from 5-10 years Seasonality stratification in all countries to define the number of rounds of SMC needed Adoption of a fifth monthly round of treatment in areas with longer seasonal transmission Adoption in areas outside of the Sahel region
Project Director	Dr André-Marie Tchouatieu